The Top 5 Biosimilars Articles for the Week of December 30

Article

The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.

Transcript

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of December 30, 2019.

Number 5: A recent study concluded that, for patients who experienced side effects or a loss of response after switching to biosimilar infliximab, a switch back to the reference product was effective.

Number 4: Anti—tumor necrosis factor therapies could play a role in alleviating or even preventing some adverse events related to immune checkpoint inhibition.

Number 3: Recent research shows that many US patients with rheumatoid arthritis who do not respond well to conventional drugs are not advancing to biologic treatment.

Number 2: Clover Biopharmaceuticals announced this week that it has dosed the first patient in a phase 3 clinical study of a proposed etanercept biosimilar.

Number 1: An official working group of the Swiss Society of Gastroenterology has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Michael Kleinrock
Michael Kleinrock
Ryan Haumschild, PharmD
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.